Noninvasive measurement of oxygen saturation of the microvascular blood in Barrett's dysplasia by use of optical spectroscopy
Background
Current investigations into endoscopic screening for the early detection of Barrett's esophageal adenocarcinoma have focused on visualization of the microvascular morphology by using narrow-band imaging (NBI). Adjustment of the center wavelength, particularly of the NBI blue imaging filter, may lead to improved image contrast, depending on the oxygen saturation of the microvascular blood of dysplastic and early cancerous Barrett's mucosa.
Objective
To perform in vivo, noninvasive measurements of the oxygen saturation of the microvascular blood for different pathologic grades of Barrett's mucosa by using differential path-length spectroscopy (DPS).
Design
DPS measurements were made on normal (n = 7), low-grade dysplastic (n = 10), high-grade dysplastic (n = 7), and cancerous (n = 4) Barrett's mucosa by using a fiber-optic probe, and were correlated to the histologic outcome of biopsy specimens taken from the same location.
Setting
Academic medical center.
Patients
Fifteen patients with Barrett's esophagus who were undergoing gastroscopy.
Interventions
Biopsy specimens were taken from suspicious areas in the esophagus.
Main Outcome Measurements
The oxygen saturation of the microvascular blood of different pathologic grades of Barrett's mucosa was assessed.
Results
The oxygen saturation of the microvascular blood remains high (approximately 90%) throughout the metaplasia-dysplasia-adenocarcinoma sequence.
Limitation
The small number of patients.
Conclusions
The current NBI blue imaging filter, centered on the peak absorption of oxyhemoglobin (415 nm), is well chosen, and little improvement in image contrast is to be expected from changes in this center wavelength.
Abbreviations: c, collection, dc, delivery-and-collection, DPS, differential path-length spectroscopy, HGD, high-grade dysplasia, HIF, hypoxia inducible factor, LGD, low-grade dysplasia, NBI, narrow-band imaging, StO2, oxygen saturation of the microvascular blood, VEGF, vascular endothelial growth factor
To access this article, please choose from the options below
DISCLOSURE: The following author disclosed financial relationships relevant to this publication: H. J. C. M. Sterenborg: CEO of Luminostix, a start-up company that aims to commercialize DPS technology. This research is supported by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs, and by the National Institutes of Health, grant NIH/NCI U54 CA104677. All other authors disclosed no financial relationships relevant to this publication.
If you want to chat with an author of this article, you may contact him at a.amelink@erasmusmc.nl.
PII: S0016-5107(08)02499-1
doi:10.1016/j.gie.2008.08.039
© 2009 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
